La cadena de opciones muestra datos clave de las opciones de acciones de Tenet Healthcare a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Tenet Healthcare..

Tenet Healthcare (NYSE:THC) Bolsa, Cadena de Opciones

Tenet Healthcare

Tenet Healthcare is a Dallas-based healthcare services organization. It operates a collection of hospitals (about 50 as of July 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the U.S., primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.

Tenet Healthcare Corporation Common Stock

Tenet Healthcare Corp

THC BIOMED INTL LTD ORD by THC BioMed Intl Ltd.

THC Biomed International Ltd

TH International Limited - Ordinary shares

TH International Ltd

Thunder Bridge Capital Partners IV, Inc. - Class A Common Stock

Thunder Bridge Capital Partners IV Inc

Thunder Bridge Capital Partners IV, Inc. - Unit

Thunder Bridge Capital Partners IV, Inc. - Warrant

THC THERAPEUTICS INC by THC Therapeutics, Inc.

THC Therapeutics Inc

Spinnaker ETF Series Cannabis ETF

Wells Fargo analyst Stephen Baxter maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Overweight and raises the price target from $195 to $205.

News

Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on Tenet Healthcare, Raises Price Target to $205

Cantor Fitzgerald analyst Sarah James maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Overweight and raises the price target from $168 to $177.

Cantor Fitzgerald Maintains Overweight on Tenet Healthcare, Raises Price Target to $177

Goldman Sachs analyst Jamie Perse maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Buy and raises the price target from $173 to $196.

Goldman Sachs Maintains Buy on Tenet Healthcare, Raises Price Target to $196

RBC Capital analyst Ben Hendrix maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Outperform and raises the price target from $174 to $183.

RBC Capital Maintains Outperform on Tenet Healthcare, Raises Price Target to $183

Truist Securities analyst David Macdonald reiterates Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Buy and raises the price target from $180 to $190.

Reiteration

Truist Securities Reiterates Buy on Tenet Healthcare, Raises Price Target to $190

UBS analyst A.J. Rice maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Buy and raises the price target from $197 to $217.

UBS Maintains Buy on Tenet Healthcare, Raises Price Target to $217

Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) has outperformed the market over the past 5 years by 28.69% on an annualized basis producing an average annual return of 42.33%. Currently, Tenet Healthcare has a market capitalization of $15.18 billion. 
Buying $1000 In THC: If an investor had bought $1000 of THC stock 5 years ago, it would be worth $6,120.94 today based on a price of $158.41 for THC at the time of writing.
<h3>Tenet Healthcare's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730228418_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Tenet Healthcare Stock In The Last 5 Years

On Tuesday,&nbsp;Tenet Healthcare Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>)&nbsp;reported <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41594927/tenet-reports-strong-third-quarter-2024-results-raises-2024-financial-outlook" rel="noreferrer noopener">third-quarter</a> sales of $5.12 billion, up around 1.1% year over year, beating the&nbsp;consensus of $5.05 billion and management <a target="_blank" href="https://www.benzinga.com/news/earnings/24/07/39934114/hospital-operator-tenet-healthcare-exceeds-earnings-expectations-announces-share-buyback-of-1-5b" rel="noreferrer noopener">guidance of $5 billion—$5.1 billion</a>.
Tenet Healthcare operates hospitals and healthcare facilities.
The company reported adjusted EPS of $2.93, up from $1.44 a year ago, beating the guidance of $2.16-$2.58 and the <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">consensus of $2.37</a>.
&#8220;Our businesses continue to produce strong results and generate robust free cash flow with same-store revenue growth and profitability well above our expectations due to the focused execution of our strategy and disciplined operations,&#8221; said Saum Sutaria, Chairman and CEO of Tenet.
Adjusted EBITDA&nbsp;was $978 million compared to $854 million a year ago, reflecting strong same-hospital admissions growth, ambulatory net revenue per case growth, favorable payer mix, and increased Medicaid supplemental <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41594927/tenet-reports-strong-third-quarter-2024-results-raises-2024-financial-outlook" rel="noreferrer noopener">revenues in Michigan</a>.
Tenet&#8217;s free cash flow was $1.78 billion for the nine months ended September 30, 2024, up 76% year over year.
Ambulatory segment revenues increased 21% to $1.14 billion, driven by net revenue per case growth, facility acquisitions, and increased service lines.
Surgical business same-facility system-wide net patient service revenues increased 8.7%, with cases up 1.0% and net revenue per case up 7.6%.
Hospital Operations and Services revenues declined 3.4% to $3.98 billion, primarily due to the impact of hospital divestitures in the first quarter of 2024. This was partially offset by strong same-hospital admissions growth, favorable payer mix, and improved pricing yield.
Same-hospital net patient service revenue per adjusted admission increased 3.3% year-over-year.
In October, the company completed the sale of its 70% majority ownership interest in Brookwood Baptist Health in Birmingham, Alabama, to Orlando Health. The completed transaction included five hospitals and other related operations.
Outlook: Tenet Healthcare revised its fiscal year 2024 revenues guidance to $20.6 billion—$20.8 billion, compared to prior guidance of $20.6 billion—$21 billion and the consensus of $20.82 billion.
The guidance includes Hospital segment sales of $16.225 billion —$16.375 billion and Ambulatory Segment sales of $4.375 billion—$4.425 billion, compared to prior guidance of $16.28 billion—$16.53 billion and $4.33 billion—$4.48 billion, respectively.
The company forecasts adjusted EPS of $11.12-$11.73 compared to prior guidance of $10.41-$11.12 and a consensus of $10.56.
Price Action:&nbsp;At last check on Tuesday, THC stock was up 12.01% at $156.18.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41596761/pfizer-q3-earnings-revenue-and-profit-on-heightened-demand-for-paxlovid-expects-10-billion-in-202" target="_blank" rel="noreferrer noopener">Pfizer Q3 Earnings: Revenue And Profit Beat On Heightened Demand For Paxlovid, Expects $10 Billion In 2024 Revenue From COVID Products</a></li>
</ul>

Earnings

Guidance

Health Care

Movers

General

Healthcare Facilities Operator Tenet Healthcare Boosts Annual Forecast On Same-store Revenue And Free Cash Flow Growth

Tenet Revises FY24 Net Operating Revenues Outlook From $20.60B - $21B To $20.60B - $20.80B (Est $20.816B), Raises Adj EPS From $10.41 - $11.12 To $11.12 - $11.73 (Est $10.56)

Tenet Expects Q4 Net Operating Revenues Of $5.007B - $5.207B (Est $5.29B), Adjusted EPS Of $2.69 - $3.31 (Est $2.88)

WIIM

Tenet Healthcare shares are trading higher after the company reported better-than-expected Q3 financial results.

Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) reported quarterly earnings of $2.93 per share which beat the analyst consensus estimate of $2.37 by 23.63 percent. This is a 103.47 percent increase over earnings of $1.44 per share from the same period last year. The company reported quarterly sales of $5.12 billion which beat the analyst consensus estimate of $5.05 billion by 1.37 percent. This is a 1.11 percent increase over sales of $5.07 billion the same period last year.

Earnings Beats

Tenet Healthcare Q3 2024 Adj EPS $2.93 Beats $2.37 Estimate, Sales $5.12B Beat $5.05B Estimate

In the current market session, Tenet Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) share price is at $141.00, after a 0.88% spike. Moreover, over the past month, the stock fell by 13.30%, but in the past year, increased by 162.96%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1730125041_0.png" alt="Past Year Chart" />

<h3>Comparing Tenet Healthcare P/E Against Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Tenet Healthcare has a lower P/E than the aggregate P/E of 32.69 of the Health Care Providers &amp; Services industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1730125041_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

P/E Ratio Insights for Tenet Healthcare

These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>ICON plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) shares plummeted 25.95% after the company reported <a href="https://www.benzinga.com//node/41500867" target="_blank" rel="noreferrer noopener">worse-than-expected results</a>. Several analysts also cut the <a href="https://www.benzinga.com/quote/iclr/analyst-ratings" target="_blank" rel="noreferrer noopener">price target on the stock</a>.</li>
<li>Genuine Parts Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPC#NYSE">GPC</a>) stock tumbled 20.21% after it reported mixed third-quarter results and cut its <a href="https://www.benzinga.com//node/41455012" target="_blank" rel="noreferrer noopener">FY24 EPS below estimates</a>. Multiple analysts cut the <a href="https://www.benzinga.com/quote/gpc/analyst-ratings" target="_blank" rel="noreferrer noopener">price target on the stock</a>.</li>
<li>Newmont Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>) shares dipped 15.97% after the company reported <a href="https://www.benzinga.com//node/41503948" target="_blank" rel="noreferrer noopener">third-quarter financial results</a>. Analysts trimmed the <a href="https://www.benzinga.com/quote/nem/analyst-ratings" target="_blank" rel="noreferrer noopener">stock&#8217;s price target</a>.</li>
<li>Tenet Healthcare Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) stock lost 14.71% last week. Several healthcare stocks and hospital operators fell in possible sympathy with HCA Healthcare, which declined on Q3 earnings.</li>
<li>Universal Health Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) stock fell 14.33% last week after the company reported <a href="https://www.benzinga.com//node/41530333" target="_blank" rel="noreferrer noopener">Q3 financial results</a>.</li>
<li>HCA Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) stock fell 12.51% after reporting <a href="https://www.benzinga.com//node/41544243" target="_blank" rel="noreferrer noopener">worse-than-expected Q3 financial results</a>. The company expects Hurricane Helene&#8217;s impact to continue in 2025.</li>
<li>TopBuild Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLD#NYSE">BLD</a>) stock lost 11.48% last week as homebuilding stocks <a href="https://www.benzinga.com//node/41317881" target="_blank" rel="noreferrer noopener">took a beating</a> due to Hurricane Milton&#8217;s impact.</li>
<li>Carlisle Companies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSL#NYSE">CSL</a>) fell 11.45% last week on <a href="https://www.benzinga.com//node/41529849" target="_blank" rel="noreferrer noopener">worse-than-expected Q3 performance</a>.</li>
<li>Teradyne, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) stock declined 11.34% after it reported <a href="https://www.benzinga.com//node/41503363" target="_blank" rel="noreferrer noopener">third-quarter financial results</a>. Some analysts trimmed the <a href="https://www.benzinga.com/quote/ter/analyst-ratings" target="_blank" rel="noreferrer noopener">price target on the stock</a>.</li>
<li>Comfort Systems USA, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIX#NYSE">FIX</a>) stock declined 11.27% after the company reported <a href="https://www.benzinga.com//node/41530044" target="_blank" rel="noreferrer noopener">worse-than-expected Q3 sales results</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/10/41560908/tesla-li-auto-and-microstrategy-are-among-top-10-large-cap-gainers-last-week-oct-21-oct-25-are-the">Tesla, Li Auto And MicroStrategy Are Among Top 10 Large Cap Gainers Last Week (Oct 21-Oct 25): Are The Others In Your Portfolio?</a></li>
</ul>

Large Cap

ICLR

Genuine Parts Company, Universal Health Services, And TopBuild Are Among Top 10 Large Cap Losers Last Week (Oct 21-Oct 25): Are The Others In Your Portfolio?

SGRY

Shares of healthcare stocks and hospital operators are trading lower in possible sympathy with HCA Healthcare, which fell after reporting Q3 eranings.

Investors with a lot of money to spend have taken a bullish stance on Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with THC, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 10 options trades for Tenet Healthcare.
This isn't normal.
The overall sentiment of these big-money traders is split between 70% bullish and 10%, bearish.
Out of all of the options we uncovered, 9 are puts, for a total amount of $536,613, and there was 1 call, for a total amount of $36,480.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $105.0 to $155.0 for Tenet Healthcare over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Tenet Healthcare's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Tenet Healthcare's whale activity within a strike price range from $105.0 to $155.0 in the last 30 days. 
<h3>Tenet Healthcare Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729780227_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>THC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$6.9</td>
<td>$6.1</td>
<td>$6.1</td>
<td>$145.00</td>
<td>$128.7K</td>
<td style="text-align: right;">946</td>
<td style="text-align: right;">131</td>
</tr>
<tr>
<td>THC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$6.9</td>
<td>$6.2</td>
<td>$6.2</td>
<td>$145.00</td>
<td>$79.8K</td>
<td style="text-align: right;">946</td>
<td style="text-align: right;">442</td>
</tr>
<tr>
<td>THC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$6.3</td>
<td>$6.2</td>
<td>$6.2</td>
<td>$145.00</td>
<td>$73.1K</td>
<td style="text-align: right;">946</td>
<td style="text-align: right;">931</td>
</tr>
<tr>
<td>THC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$6.5</td>
<td>$6.2</td>
<td>$6.2</td>
<td>$145.00</td>
<td>$62.0K</td>
<td style="text-align: right;">946</td>
<td style="text-align: right;">716</td>
</tr>
<tr>
<td>THC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$6.9</td>
<td>$6.2</td>
<td>$6.2</td>
<td>$145.00</td>
<td>$48.9K</td>
<td style="text-align: right;">946</td>
<td style="text-align: right;">521</td>
</tr>
</tbody>
</table>

<h3>About Tenet Healthcare</h3>
Tenet Healthcare is a Dallas-based healthcare services organization. It operates a collection of hospitals (about 50 as of July 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the U.S., primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
In light of the recent options history for Tenet Healthcare, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Tenet Healthcare's Current Market Status</h3>
<ul>
<li>With a trading volume of 208,882, the price of THC is down by -2.13%, reaching $154.26.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 5 days from now.</li>
</ul>
<h3>What The Experts Say On Tenet Healthcare</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $182.2.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $168. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $168. 
&#x2A; An analyst from Truist Securities persists with their Buy rating on Tenet Healthcare, maintaining a target price of $180. 
&#x2A; Reflecting concerns, an analyst from Keybanc lowers its rating to Overweight with a new price target of $200. 
&#x2A; An analyst from Wells Fargo persists with their Overweight rating on Tenet Healthcare, maintaining a target price of $195. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Tenet Healthcare, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Behind the Scenes of Tenet Healthcare's Latest Options Trends

Looking into the current session, Tenet Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) shares are trading at $154.83, after a 1.77% decrease. Over the past month, the stock decreased by 6.13%, but over the past year, it actually went up by 191.47%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2024/1729779314_0.png" alt="Past Year Chart" />

<h3>Tenet Healthcare P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 34.07 in the Health Care Providers &amp; Services industry, Tenet Healthcare Inc. has a lower P/E ratio of 5.74. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1729779314_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

A Look Into Tenet Healthcare Inc's Price Over Earnings

Throughout the last three months, 15 analysts have evaluated Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $176.47, a high estimate of $200.00, and a low estimate of $168.00. Observing a 12.81% increase, the current average has risen from the previous average price target of $156.43. 
<img src="https://www.benzinga.com/files/images/story/2024/1729612884_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of Tenet Healthcare by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$195.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$180.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$200.00</td>
<td>-</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$168.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$168.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$168.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$168.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>A.J. Rice</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$197.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Jamie Perse</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$173.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$175.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$171.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>Jason Cassorla</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$171.00</td>
<td>$139.00</td>
</tr>
<tr>
<td>John Ransom</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$175.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$170.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$168.00</td>
<td>$112.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Tenet Healthcare. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Tenet Healthcare compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Tenet Healthcare's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Tenet Healthcare's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/THC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Tenet Healthcare analyst ratings.</a>
<h2>Unveiling the Story Behind Tenet Healthcare</h2>
Tenet Healthcare is a Dallas-based healthcare services organization. It operates a collection of hospitals (about 50 as of July 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the U.S., primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
<h3>Tenet Healthcare's Economic Impact: An Analysis</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Over the 3 months period, Tenet Healthcare showcased positive performance, achieving a revenue growth rate of 0.41% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Tenet Healthcare's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 5.08%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Tenet Healthcare's ROE stands out, surpassing industry averages. With an impressive ROE of 7.48%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Tenet Healthcare's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.89%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a high debt-to-equity ratio of 3.7, Tenet Healthcare faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Tenet Healthcare Stands With Analysts

Ratings for Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) were provided by 15 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $176.47, a high estimate of $200.00, and a low estimate of $168.00. Witnessing a positive shift, the current average has risen by 12.81% from the previous average price target of $156.43.
<img src="https://www.benzinga.com/files/images/story/2024/1729612814_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Tenet Healthcare among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$195.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$180.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$200.00</td>
<td>-</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$168.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$168.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$168.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$168.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>A.J. Rice</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$197.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Jamie Perse</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$173.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$175.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$171.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>Jason Cassorla</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$171.00</td>
<td>$139.00</td>
</tr>
<tr>
<td>John Ransom</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$175.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$170.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$168.00</td>
<td>$112.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Tenet Healthcare. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Tenet Healthcare compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Tenet Healthcare's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Tenet Healthcare's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/THC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Tenet Healthcare analyst ratings.</a>
<h2>About Tenet Healthcare</h2>
Tenet Healthcare is a Dallas-based healthcare services organization. It operates a collection of hospitals (about 50 as of July 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the U.S., primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
<h3>Unraveling the Financial Story of Tenet Healthcare</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Over the 3 months period, Tenet Healthcare showcased positive performance, achieving a revenue growth rate of 0.41% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 5.08%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 7.48%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.89%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Tenet Healthcare's debt-to-equity ratio stands notably higher than the industry average, reaching 3.7. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Tenet Healthcare: 15 Analysts Share Their Views

Wells Fargo analyst Stephen Baxter maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Overweight and raises the price target from $175 to $195.

Wells Fargo Maintains Overweight on Tenet Healthcare, Raises Price Target to $195

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Stryker (SYK – Research Report), Tenet Healthcare ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Stryker (SYK), Tenet Healthcare (THC) and SAGE Therapeutics (SAGE)

UBS raised the firm's price target on Tenet Healthcare (THC) to $217 from $197 and keeps a Buy rating on the shares. Tenet reported a strong perfor...

Tenet Healthcare price target raised to $217 from $197 at UBS

Steve Baxter, an analyst from Wells Fargo, maintained the Buy rating on Tenet Healthcare (THC – Research Report). The associated price target remai...

Buy Rating Justified for Tenet Healthcare Amidst Strong EBITDA Growth and Operational Performance

Analyst Whit Mayo of Leerink Partners reiterated a Buy rating on Tenet Healthcare (THC – Research Report), with a price target of $202.00. Whit May...

Strong Financial Performance and Growth Potential Drive Positive Outlook for Tenet Healthcare

Truist raised the firm's price target on Tenet Healthcare (THC) to $190 from $180 and keeps a Buy rating on the shares. The firm is bullish after t...

Tenet Healthcare price target raised to $190 from $180 at Truist

IVV: S&P 500 Dashboard For November

Tenet Healthcare: Targeting More Stable Demand In High-Acuity Services

Wells Fargo raised the firm's price target on Tenet Healthcare (THC) to $205 from $195 and keeps an Overweight rating on the shares. Following Q3 e...

Tenet Healthcare price target raised to $205 from $195 at Wells Fargo

In a report released yesterday, Steve Baxter from Wells Fargo maintained a Buy rating on Tenet Healthcare (THC – Research Report), with a price tar...

Comments

Tenet Healthcare

Tenet Healthcare (THC) Opciones

Tenet Healthcare (NYSE:THC) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL